KR890012667A - 부작용 예방방법 - Google Patents

부작용 예방방법 Download PDF

Info

Publication number
KR890012667A
KR890012667A KR1019890001312A KR890001312A KR890012667A KR 890012667 A KR890012667 A KR 890012667A KR 1019890001312 A KR1019890001312 A KR 1019890001312A KR 890001312 A KR890001312 A KR 890001312A KR 890012667 A KR890012667 A KR 890012667A
Authority
KR
South Korea
Prior art keywords
igf
insulin
administered
side effects
amount
Prior art date
Application number
KR1019890001312A
Other languages
English (en)
Other versions
KR0131087B1 (ko
Inventor
루돌프 프뢰쉬 에른스트
굴러 한스-페터
쉬미드 크리스토프
짭프 유르겐
Original Assignee
에른스트 알터
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에른스트 알터, 시바-가이기 에이지 filed Critical 에른스트 알터
Publication of KR890012667A publication Critical patent/KR890012667A/ko
Application granted granted Critical
Publication of KR0131087B1 publication Critical patent/KR0131087B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음.

Description

부작용 예방방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 피검자 1에 재조합 IGF I을 체중 1㎏ 및 1시간당 32.0㎍의 속도로 연속 피하 주입한 후 주입 첫 번째 날의 혈당 및 유리 IGF I의 혈청내 농도의 비교도이다.
제2도는 두 피검자에 체중 1㎏ 및 1시간당 20.0㎍용량의 재조합 IGF I의 일정한 피하 주입 6일 전, 6일 후의 측정된 모든 IGF I의 혈청내 농도의 비교도이다.
제3도는 두 피검자에 체중 1㎏ 및 1시간당 20㎍ 용량의 재조합 IGF I의 일정한 피하 주입 6일 전, 6일 동안 및 6일 후의 C-펩타이드 및 인슐린의 혈청내 농도의 비교도이다.

Claims (16)

  1. 유효량의 IGF I 및 정량보다 소량의 인슐린을 투여함을 특징으로 하여, 인슐린의 처방으로 당뇨병 환자에 유발되는 과인슐린증의 부작용을 치료 및 예방하는 방법.
  2. 유효량의 IGF I를 투여함을 특징으로 하여, 유형 2의 당뇨병 환자, 비만증 환자 또는 과지방혈증 환자를 치료하는 방법.
  3. 제1항 또는 제2항에 있어서, 재조합 IGF I을 사용하는 방법.
  4. 제1항 또는 제2항에 있어서, IGF I을 약 24㎍/㎏/일 내지 약 720㎍/㎏/일 의 양으로 투여하는 방법.
  5. 제1항에 있어서, IGF I과 함께 인슐린을 단독 사용시의 양보다 소량으로 투여하는 방법.
  6. 제1항에 있어서, IGF I과 함께 인슐린을 자체적으로 혈당에 영향을 미치지 않는 양으로 투여하는 방법.
  7. 제1항에 있어서, IGF I과 함께 인슐린을 0.2IU/㎏/24시간 내지 약 0.5IU/㎏/24시간의 양을 투여하는 방법.
  8. 제1항 또는 제2항에 있어서, IGF I을 미니 펌프(minipump)를 통하여 피하 또는 정맥내 주입하는 방법.
  9. 제1항 또는 제2항에 있어서, IGF I을 약 1㎍/㎏/시간 내지 약 24μ/㎏/시간의 용량으로 피하, 정맥내 또는 근육내 투여하는 방법.
  10. IGF I 및 인슐린을 함유하는 상승작용성 당뇨병 치료 약제 조성물.
  11. IGF I 및 정량보다 소량의 인슐린을 통상적인 방법에 따라 약학적으로 가공함을 특징으로 하여, 인슐린의 처방으로 당뇨병 환자에 유발되는 과인슐린증의 부작용을 치료 및 예방하기 위한 약제를 제조하는 방법.
  12. 인슐린의 처방으로 당뇨병 환자에 유발되는 과인슐린증의 부작용을 예방하기 위한 제10항에 따른 약제 조성물의 용도.
  13. IGF I을 통상적인 방법에 따라 약학적으로 가공함을 특징으로 하며, 유형 2의당뇨병 환자, 비만증 환자 또는 과지방혈증 환자의 치료용 약제를 제조하는 방법.
  14. 유형 2의 당뇨병 환자, 비만증 환자 및 과지방혈증 환자의 부작용을 예방하여 사용지시서를 포함할 수 있는 약제를 제조하기 위한 IGF I의 용도.
  15. IGF I 및 인슐린을 함유하는 상승 작용성 조성물을 제조하기 위한 IGF I의 용도.
  16. IGF I 또는 IGF I과 인슐린과의 조성물을 함유하며, 사용 지시서를 포함할 수 있는 제제 또는 팩(pack).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890001312A 1988-02-05 1989-02-04 인슐린 유사성 성장인자 i을 함유하는 약제학적 제제 KR0131087B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP88810072.4 1988-02-05
EP88810072 1988-02-05

Publications (2)

Publication Number Publication Date
KR890012667A true KR890012667A (ko) 1989-09-18
KR0131087B1 KR0131087B1 (ko) 1998-04-17

Family

ID=8200571

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890001312A KR0131087B1 (ko) 1988-02-05 1989-02-04 인슐린 유사성 성장인자 i을 함유하는 약제학적 제제

Country Status (13)

Country Link
US (1) US4988675A (ko)
EP (1) EP0331630B1 (ko)
JP (1) JP2831017B2 (ko)
KR (1) KR0131087B1 (ko)
AU (1) AU624595B2 (ko)
CA (1) CA1336815C (ko)
DE (1) DE68905205T2 (ko)
DK (1) DK169233B1 (ko)
IE (1) IE63163B1 (ko)
IL (1) IL89166A0 (ko)
NZ (1) NZ227857A (ko)
PH (1) PH26085A (ko)
ZA (1) ZA89855B (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
WO1993025226A1 (en) * 1992-06-08 1993-12-23 Kabi Pharmacia Ab Use of growth factor igf-i and/or igf-ii
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
ATE143267T1 (de) * 1992-10-29 1996-10-15 Genentech Inc Methode zur behandlung oder verhütung von fettleibigkeit
EP0642350A4 (en) * 1993-01-25 1995-06-28 Beth Israel Hospital PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS.
US5446024A (en) * 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US5916569A (en) * 1997-03-26 1999-06-29 E. Martin Spencer Human erectile dysfunction and methods of treatment
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
JP3971108B2 (ja) * 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
IL145597A0 (en) 1999-04-08 2002-06-30 Genentech Inc Composition based on oppositely-charged polypeptides
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
WO2001087323A2 (en) * 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
CA2419561A1 (en) * 2000-08-29 2002-03-07 Colorado State University Research Foundation Method for treating the central nervous system by administration of igf structural analogs
EP1358209B1 (en) * 2001-02-09 2006-12-27 Genentech, Inc. Crystallization of igf-1
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
CA2702192A1 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP5108303B2 (ja) * 2003-08-21 2012-12-26 テルシカ インコーポレーティッド インスリン様成長因子（ｉｇｆ−ｉ）のレベル上昇による内臓脂肪の低下方法
ES2788699T3 (es) * 2004-08-30 2020-10-22 Ipsen Biopharmaceuticals Inc Procedimiento y dispositivo para diagnosticar y tratar trastornos de deficiencia del factor de crecimiento similar a la insulina
KR102288366B1 (ko) * 2018-03-09 2021-08-10 경북대학교 산학협력단 한속단 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) * 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna

Also Published As

Publication number Publication date
US4988675A (en) 1991-01-29
IE890357L (en) 1989-08-05
JP2831017B2 (ja) 1998-12-02
DK52189A (da) 1989-08-06
IL89166A0 (en) 1989-09-10
DK52189D0 (da) 1989-02-03
AU624595B2 (en) 1992-06-18
KR0131087B1 (ko) 1998-04-17
PH26085A (en) 1992-02-06
DE68905205T2 (de) 1993-07-22
AU2899989A (en) 1989-08-10
CA1336815C (en) 1995-08-29
EP0331630B1 (en) 1993-03-10
EP0331630A1 (en) 1989-09-06
DK169233B1 (da) 1994-09-19
ZA89855B (en) 1989-10-25
NZ227857A (en) 1992-04-28
JPH01233227A (ja) 1989-09-19
DE68905205D1 (de) 1993-04-15
IE63163B1 (en) 1995-03-22

Similar Documents

Publication Publication Date Title
KR890012667A (ko) 부작용 예방방법
Raskin et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
Raskin et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
KR890012666A (ko) 신장 질환의 치료방법
Vignati et al. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non—insulin-dependent diabetes mellitus
Reinhart et al. Insulin glargine: A new long-acting insulin product
US8003605B2 (en) Minimising body weight gain in insulin treatment
KR20170123699A (ko) 제2형 진성 당뇨병 환자의 치료
KR920700227A (ko) 초고활성 인체 인슐린 동족체
Saito et al. Semaglutide, a newly available glucagon‐like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes.
Welle et al. Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus
Sonnenberg et al. Human and porcine regular insulins are equally effective in subcutaneous replacement therapy: results of a double-blind crossover study in type I diabetic patients with continuous subcutaneous insulin infusion
KR910700069A (ko) Gm-csf를 사용한 백혈구 기능장애의 치료
LERNER The augmentation effect of secretin on the insulin responses to known stimuli: specificity for glucose
Dimitriadis et al. Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus
Haliloglu et al. Retrospective evaluation of insulin degludec/insulin aspart co-formulation therapy in patients with type 2 Diabetes Mellitus: A single-center experience
WO2005021026A2 (en) Methods for treating or ameliorating ghrelin-associated diseases and disorders
Chantelau et al. A Case of lipoatrophy with human insulin-therapy
Schusdziarra et al. Somatostatin analogs as glucagon suppressants in diabetes
Landgraf-Leurs et al. Counterregulatory hormone release after human and porcine insulin in healthy subjects and patients with pituitary disorders
Forlani et al. Effects of mixing short-and intermediate-acting insulins on absorption course and biologic effect of short-acting preparation
DE4201196C2 (de) Arzneimittel zur Behandlung der Polyneuropathie
Vischer et al. A randomized, double-blind trial comparing a pulse of 1000 with 250 mg methylprednisolone in rheumatoid arthritis
Conte et al. Glucagon effect on plasma Mg concentration
Blonde Easing the transition to insulin therapy in people with type 2 diabetes

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20071123

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee